ArticleTranslational pediatrics2026
A female manifesting carrier of DMD with exon 45 deletion: a case report.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Duchenne muscular dystrophy (DMD) is a rare X-linked recessive hereditary disease that overwhelmingly affects males, while symptomatic female carriers are rarely encountered in clinical practice. Persistent elevation of liver enzymes is often misattributed to primary liver injury in young children, which may delay the recognition of underlying myogenic disorders like DMD. Case Description: We herein report the case of a 3-year-old female manifesting carrier of DMD. The patient initially presented with continuously raised liver transaminases and drastically elevated serum creatine kinase (CK). Further physical examination found delayed motor developmental milestones. Genetic testing confirmed an unreported novel deletion variant in exon 45 of the DMD gene. After all hepatic pathogenic factors were ruled out, the child was finally diagnosed with symptomatic DMD carrier status. Conclusions: For pediatric cases featuring unexplained hypertransaminasemia combined with high CK values, clinicians should stay highly alert to the possibility of DMD. Dynamic serial CK monitoring and full-scale genetic analysis should be arranged without delay to achieve early diagnosis and timely intervention, which can effectively optimize long-term prognosis for affected children.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.